Skip to main content
SpringerLink
Log in

Targeting the IL-2 receptor with antibodies or chimeric toxins

  • Chapter
Modern Immunosuppressives

Part of the book series: Milestones in Drug Therapy MDT ((MDT))

  • 101 Accesses

Abstract

Although various mouse anti-rat and rat anti-mouse monoclonal antibodies (mAbs) produce profound immunosuppressive effects, the experience with rodent anti-human mAb has been somewhat disappointing. The impetus for creating chimeric or humanized mAbs or fusion proteins to be used as immunosuppressive agents in allograft recipients stems directly from the clinical experience with rodent antihuman mAbs. With the exception of antibodies directed against proteins of the TCR/CD3 complex, murine mAbs have failed to deliver on their many potential advantages for treating or preventing rejection. The favorable attributes of chimeric or humanized mAbs include: (i) high specificity and affinity; (ii) long circulating half-lives; and (iii) a variety of mechanisms by which they can mediate an immunosuppressive effect. Cytolytic immune effector mechanisms of the host, antibody-mediated cell-mediated cytotoxicity (ADCC), and complement-mediated cytotoxicity (CDC) can theoretically be recruited directed against antibody coated target cells. Moreover, mAbs can interrupt signaling at the cell surface by blocking key receptor sites.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Chatenoud L, Baudrihay MF, Chkoff N, Kreis H, Goldstein G, Bach J-F (1986) Restriction of the human in vivo immune response against the mouse monoclonal antibody OKT3. J Immunol 137: 830–838

    PubMed  CAS  Google Scholar 

  2. Jaffers GJ, Fuller TC, Cosimi AB, Russell PS, Winn HJ, Colvin RB (1986) Monoclonal antibody therapy anti-idiotypic and non-anti-idiotypic antibodies to OKT3 arising despite intense immunosuppression. Transplantation 41: 572–578

    Article  PubMed  CAS  Google Scholar 

  3. Thistlethwaite JR, Stuart JK, Mayes JT, Gaber AO, Woodle S, Buckingham MR, Stuart FP (1988) Monitoring and complications of monoclonal therapy: complications and monitoring of OKT3 therapy. Amer J Kidney Dis 11: 112–119

    Google Scholar 

  4. Morrison SL, Johnson MJ, Herzenberg LA, Oi VT (1984) Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Nall Acad Sci USA 81: 6851–6855

    Article  CAS  Google Scholar 

  5. Jones PT, Dear PH, Foote J, Neuberger MS, Winter G (1986) Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321: 522–525

    Article  PubMed  CAS  Google Scholar 

  6. Smith KA (1987) The two chain structure of high-affinity IL-2 receptors. Immunol Today 8: 11–13

    Article  CAS  Google Scholar 

  7. Cantrell PA, Smith KA (1984) The interleukin-2 T-cell system: a new cell growth model. Science 224: 1312–1316

    Article  PubMed  CAS  Google Scholar 

  8. Leonard WJ, Depper JM, Uchiyama T, Smith KA, Waldmann TA, Greene WC (1982) A monoclonal antibody that appears to recognize the receptor for human T-cell growth factor; partial characterization of the receptor. Nature 300: 267–269

    Article  PubMed  CAS  Google Scholar 

  9. Maddock EO, Maddock SW, Kelley VE, Strom TB (1985) Rapid stereospecific stimulation of lymphocytic metabolism by interleukin-2. J Immunol 135: 4004–4008

    PubMed  CAS  Google Scholar 

  10. Tsudo M, Kozak RW, Goldman CK, Waldmann TA (1986) Demonstration of a non-Tac peptide that binds interleukin 2: a potential participant in a multichain interleukin 2 receptor complex. Proc Natl Acad Sci USA 83: 9694–9698

    Article  PubMed  CAS  Google Scholar 

  11. Takeshita T, Asao H, Ohtani K, Ishii N, Kumaki S, Tanaka N, Munakata H, Nakamura M, Sugamura K (1992) Cloning of the gamma chain of the human IL-2 receptor. Science 257: 379–382

    Article  PubMed  CAS  Google Scholar 

  12. Strom TB, Kelley VR, Murphy JR, Nichols N, Woodworth TG (1993) Interleukin-2 receptor-directed therapies: antibody-or cytokine-based targeting molecules. Annu Rev Med 44: 343–353

    Article  PubMed  CAS  Google Scholar 

  13. Waldmann TA, O’Shea J (1998) The use of antibodies against the IL-2 receptor in transplantation. Curr Opin Immunol 10: 507–512

    Article  PubMed  CAS  Google Scholar 

  14. Kirkman RL, Shapiro ME, Carpenter CB, Milford EL, Ramos EL, Tilney NL, Waldmann TA, Zimmerman CE, Strom TB (1989) Early experience with anti-Tac, an antihuman IL-2 receptor mAb. Transplantation 21: 1766–1768

    CAS  Google Scholar 

  15. Soulillou JP, Peyronnet P, Le Mauff B, Hourmant M, Olive D, Mawas C, Delaage M, Hirn M, Jacques Y (1987) Prevention of rejection of kidney transplants by mAb directed against interleukin 2. Lancet 1: 1339–1342

    Article  PubMed  CAS  Google Scholar 

  16. Soulillou JP, Cantarovich D, Le Mauff B, Giral M, Robillard N, Hourmant M, Hirn M, Jacques Y (1990) Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts. N Engl J Med 322: 1175–1182

    Article  PubMed  CAS  Google Scholar 

  17. Kirkman RL, Shapiro ME, Carpenter CB, McKay DB, Milford EL, Ramos EL, Tilney NL, Waldmann TA, Zimmerman CE, Strom TB (1991) A randomized prospective trial of anti-Tac monoclonal antibody in human renal transplantation. Transplantation 51: 107–113

    Article  PubMed  CAS  Google Scholar 

  18. Van Gelder T, Zietse R, Mulder AH, Yzermans JN, Hesse CJ, Vaessen LM, Weimar W (1995) A variable blind study of uroclonal anti-interleukin-2 receptor antibody (BT563) administration to prevent acute rejection after kidney transplantation. Transplantation 60: 248–252

    Article  PubMed  Google Scholar 

  19. Nashan B, Schlitt HJ, Schwinzer R, Ringe B, Kuse E, Tusch G, Wonigeit K, Pichlmayr R (1996) Immunoprophylaxis with a monoclonal anti-IL-2 receptor antibody in liver transplant patients. Transplantation 61: 546–554

    Article  PubMed  CAS  Google Scholar 

  20. Langren JM, Nussler NC, Neumann U, Guckelberger O, Lohmann R, Radtke A, Jonas S, Klupp J, Steinmuller T, Lobeck H et al (1997) A prospective randomized trial comparing interleukin-2 receptor antibody versus antithymocyte globulin as part of a quadruple immunosuppressive induction therapy following orthopic liver transplantation. Transplantation 63: 1772–1781

    Article  Google Scholar 

  21. Amlot PL, Rawslings E, Fernando ON, Griffin PH, Heinrich G, Schreier MH, Castaigue JP, Moore R, Sceny P (1995) Prolonged action of a chimeric interleukin-2 receptor [CD25] monoclonal antibody used in cadaveric renal transplantation. Transplantation 60: 748–756

    Article  PubMed  CAS  Google Scholar 

  22. Queen C, Schneider WP, Selick HE, Payne PW, Landolfi NF, Duncan JF, Avdalovic NM, Levitt M, Junghans RP, Waldmann TA (1989) A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci USA 86: 10 029–10 033

    Article  CAS  Google Scholar 

  23. Kahan BD, Rajagopalan PR, Hall M (1999) Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group. Transplantation 72: 276–284

    Article  Google Scholar 

  24. Nashan B, Moore R, Amlot P, Schmidt A-G, Abaywickrama K, Soulillou J-P for the CHIB 201 International Study Group (1997) Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet 350: 1193–1198

    Article  PubMed  CAS  Google Scholar 

  25. Vincenti F, Kirkman R, Light S, Bumgardner G, Pescovitz M, Halloran P, Neylan J, Wilkinson A, Ekberg H, Gaston R et al (1998) Interleukin-2 receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 338: 161–165

    Article  PubMed  CAS  Google Scholar 

  26. Choe S, Bennett MJ, Fujii G, Curmi PM, Kantardjieff KA, Collier RJ, Eisenberg D (1992) The crystal structure of diphtheria toxin. Nature 357: 216–222

    Article  PubMed  CAS  Google Scholar 

  27. Pastan I, Willingham MC, FitzGerald DJ (1986) Immunotoxins. Cell 47: 641–648

    Article  PubMed  CAS  Google Scholar 

  28. Olsnes S, Sandrig K, Petersen OW, VanDeurs B (1989) Immunotoxins - entry into cells and mechanisms of action. Immunol Today 10: 291–295

    PubMed  CAS  Google Scholar 

  29. Williams DP, Regier D, Akiyoshi D, Genbauffe F, Murphy JR (1988) Design, synthesis and expression of a human interleukin-2 gene-incorporating the codon usage bias found in highly expressed Escherichia coli genes. Nucl Acid Res 16: 10 453–10 467

    Article  CAS  Google Scholar 

  30. Siegall CB, Chaudhary VK, FitzGerald DJ, Pastan I (1988) Cytotoxic activity of an interleukin-6 Pseudomonas exotoxin fusion protein on human myeloma cells. Proc Nati Acad Sci USA 85: 9738–9742

    Article  CAS  Google Scholar 

  31. Williams DP, Parker K, Bacha P, Bishai W, Borowski M, Genbauffe F, Strom TB, Murphy JR (1987) Diphtheria toxin receptor binding domain substitution with interleukin-2: genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein. Protein Eng 1: 493–498

    Article  PubMed  CAS  Google Scholar 

  32. Williams DPSnider CE, Strom TB, Murphy JR (1990) Structure/function analysis of interleukin-2-toxin (DAB486-IL-2). Fragment B sequences required for the delivery of fragment A to the cytosol of target cells. J Biol Chem 265: 11 885–11 889

    PubMed  CAS  Google Scholar 

  33. Lorberboum-Gaiski H, FitzGerald D, Chaudhary V, Adhya S Pastan I (1988) Cytotoxic activity of an interleukin-2 Pseudomonas exotoxin chimeric protein produced in Escherichia coli. Pmc Natl Acad Sci USA 85: 1922–1926

    Article  Google Scholar 

  34. Murphy JR, Bishai W, Borowski A, Miyanohara A, Boyd J, Nagle S (1986) Genetic construction, expression, and melanoma-selective cytotoxicity of a diphtheria toxin-related alpha-melanocytestimulating hormone fusion protein. Proc Natl Acad Sci USA 83: 8258–8262

    Article  PubMed  CAS  Google Scholar 

  35. Chaudhary VK, FitzGerald DJ, Adhya S, Pastan I. Activity of a recombinant fusion protein between transforming growth factor type alpha and Pseudomonas toxin. Proc Nail Acad Sci USA 84: 4538–4542

    Article  Google Scholar 

  36. Chaudhary VK, Mizukami T, Fuerst TR, FitzGerald DJ, Moss B, Pastan I, Berger EA (1988) Selective killing of HIV-infected cells by recombinant human CD4-Pseudomonas exotoxin hybrid protein. Nature 335: 369–372

    Article  PubMed  CAS  Google Scholar 

  37. Bacha P, Williams DP, Waters C, Williams JM, Murphy JR, Strom TB (1988) Interleukin-2 receptor targeted cytotoxicity: interleukin-2 receptor mediated action of a diphtheria toxin-related interleukin-2 fusion protein. J Exp Med 67: 612–622

    Article  Google Scholar 

  38. LeMaistre CF, Saleh MN, Kuzel TM, Foss F, Platanias LC, Schwartz G, Ratain M, Rook A, Freytes CO, Craig F et al (1988) Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2. Blood 91: 399–405

    Google Scholar 

  39. Gottlieb SL, Gilicaudeau P, Johnson R, Eftis A, Woodworth TG, Gottlieb AB, Kreuger JG (1995) The response of psoriasis to a lymphocyte selective toxin DAB389 IL-2 suggests a primary immune but not keratinocyte, pathogenic basis. Nat Med 1: 442–447

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Harvard Medical School, Division of Immunology, Beth Israel Deaconess Medical Center, Research North, Room 380, P.O. Box 15707, Boston, MA, 02215, USA

    Terry B. Strom

Authors
  1. Terry B. Strom
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Novartis Pharma AG, USA

    Henk-Jan Schuurman

  2. Novartis Pharma AG, Basel, 4002, Switzerland

    Gilles Feutren

  3. Immunologie Clinique, Hôpital Necker, 161 Rue de Sèvres, Paris Cedex 15, France

    Jean-François Bach

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Springer Basel AG

About this chapter

Cite this chapter

Strom, T.B. (2001). Targeting the IL-2 receptor with antibodies or chimeric toxins. In: Schuurman, HJ., Feutren, G., Bach, JF. (eds) Modern Immunosuppressives. Milestones in Drug Therapy MDT. Birkhäuser, Basel. https://doi.org/10.1007/978-3-0348-8352-8_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-0348-8352-8_7

  • Publisher Name: Birkhäuser, Basel

  • Print ISBN: 978-3-0348-9530-9

  • Online ISBN: 978-3-0348-8352-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation